Revisiting Apathy in Alzheimer’s Disease: From Conceptualization to Therapeutic Approaches
Author(s) -
Antônio Lúcio Teixeira,
Mitzi M. Gonzales,
Leonardo Cruz de Souza,
Sara L. Weisenbach
Publication year - 2021
Publication title -
behavioural neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.859
H-Index - 48
eISSN - 1875-8584
pISSN - 0953-4180
DOI - 10.1155/2021/6319826
Subject(s) - apathy , conceptualization , psychology , cognition , disease , alzheimer's disease , affect (linguistics) , dementia , clinical psychology , cognitive psychology , psychiatry , psychotherapist , medicine , communication , artificial intelligence , computer science
Apathy is a neurobehavioral syndrome characterized by impaired motivation for goal-directed behaviors and cognitive activity, alongside blunted affect. Apathy is a common neuropsychiatric syndrome in Alzheimer's disease (AD), with a 5-year prevalence over 70%. Apathy also serves as a prognostic indicator, correlating with the progression of AD. Despite advances in its conceptualization and understanding of its neural basis, there is very limited empirical evidence to support the available strategies for the treatment of apathy in AD. Given its complex pathophysiology, including distinct substrates for different apathy dimensions (affective, cognitive, and behavioral), it is unlikely that a single pharmacological or nonpharmacological strategy will be effective for all cases of apathy in AD. High-quality evidence research is needed to better understand the role of specific strategies aiming at a personalized approach.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom